D. E. Shaw & Co., Inc. Xeris Biopharma Holdings, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 985,015 shares of XERS stock, worth $3.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

985,015

Holding current value

$3.04 Million

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.06 - $2.96 $962,001 - $1.38 Million	466,991 Added 90.15%	985,015 $2.81 Million
Q2 2024 Aug 14, 2024	SELL	$1.7 - $2.45 $321,277 - $463,018	-188,987 Reduced 26.73%	518,024 $1.17 Million
Q1 2024 May 15, 2024	SELL	$2.04 - $3.22 $709,101 - $1.12 Million	-347,599 Reduced 32.96%	707,011 $1.56 Million
Q4 2023 Feb 14, 2024	BUY	$1.47 - $2.36 $263,424 - $422,912	179,200 Added 20.47%	1,054,610 $2.48 Million
Q3 2023 Nov 14, 2023	BUY	$1.8 - $2.69 $268,846 - $401,775	149,359 Added 20.57%	875,410 $1.63 Million
Q2 2023 Aug 14, 2023	BUY	$1.82 - $2.98 $1.08 Million - $1.77 Million	593,872 Added 449.29%	726,051 $1.9 Million
Q1 2023 May 15, 2023	SELL	$1.03 - $1.63 $31,106 - $49,226	-30,200 Reduced 18.6%	132,179 $215,000
Q4 2022 Feb 14, 2023	BUY	$1.14 - $1.65 $5,841 - $8,454	5,124 Added 3.26%	162,379 $215,000
Q3 2022 Nov 14, 2022	BUY	$1.37 - $1.93 $148,497 - $209,196	108,392 Added 221.83%	157,255 $245,000
Q2 2022 Aug 15, 2022	SELL	$1.48 - $2.64 $148,270 - $264,483	-100,183 Reduced 67.22%	48,863 $75,000
Q1 2022 May 16, 2022	BUY	$2.0 - $2.87 $298,092 - $427,762	149,046 New	149,046 $382,000

Others Institutions Holding XERS

# of Institutions

141

Shares Held

59.9M

Call Options Held

148K

Put Options Held

45.7K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $420M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account